Friday 11th September

Thanks to substantial investments in manufacturing, sophisticated regulatory infrastructure and its unparalleled connectivity to the Asia-Pacific’s diverse markets, Singapore has established itself as a preeminent location for pharmaceutical and business events. The pharma sector in the APAC region has been valued at USD $497.45bn as of 2026, with projections set to hit USD $916.08bn within a decade. 

This regional growth reflects a population with increasing healthcare access, including older demographics creating significant demand for chronic disease treatments, thanks to substantial investments from the government in infrastructure and manufacturing. However, the APAC’s pharma markets are as diverse economically as they are geographically, creating complexity for international companies looking to do business in the region. It’s against this backdrop that Singapore truly stands out, providing a neutral, accessible and business-friendly location that’s home to a significant concentration of pharma manufacturing and research & development facilities, as well as many brands’ regional headquarters. It also happens to be where the inaugural Pharmapack Asia conference will be taking place from 3-4 November 2026.

Read on to discover more about what has made Singapore such a gateway for the region’s pharma industry, and how companies worldwide are capitalising on its business landscape.

The environmental advantage: regulatory expertise and IP protection

Singapore consistently ranks among the world's most business-friendly jurisdictions, and the World Bank has ranked it the top country globally for operational efficiency, which the 2025 B-Ready report notes “tends to be higher in economies experiencing high growth.” One key advantage the country has over others in the APAC region is its dedicated IP strategy, a decade-long “blueprint to strengthen the nation’s position as a global IP and innovation hub,” called SIPS 2030.

With a three-pronged approach split between hub, business and jobs, the primary goal of SIPS 2030 is simple: “position Singapore as a node…supporting ASEAN [and] connecting to the world.” On an international level, Singapore is a signatory to major global IP treaties including the Paris Convention, Patent Cooperation Treaty and the TRIPS Agreement. The country’s patent office typically processes applications within 2-4 years, which is comparable with other major global patent hubs.

Singapore’s legal system also puts a great deal of priority on enforcing IP rights, offering reassurance to pharma companies that any cases will be handled with technical expertise and jurisprudence. The country’s infrastructure is also geared towards creating an open environment for discussions around licensing, partnerships and collaborative development, with the promise of confidence and protection at every step.

The framework of regulations behind Singapore’s pharma industry balances international best practice with efficiency and robust scientific thinking. Singapore’s pharma regulators the Health Sciences Authority (HSA) is aligned with their global counterparts, ensuring efficient market access for pharmaceutical products with established safety and efficacy profiles whilst maintaining rigorous standards ensuring patient safety.

Geographic connectivity and access to regional manufacturing centres

Singapore's geographic position sits at the crossroads of several major Asian markets and its connectivity is bolstered by its status as a global aviation and maritime hub. This provides a base for the country to offer seamless logistical benefits for all industries, but is especially useful for the pharma industry thanks to the gateway it offers to manufacturing operations elsewhere in the APAC region. This facilitates collaboration by providing easy access to resources for business development, technology assessment and supplier engagement, as well as talent and patient pools to further boost the region’s power in the pharma space.

With more than 60 biopharma manufacturing facilities currently in operation, Singapore's own pharma manufacturing sector is thriving, including ones run by major multinationals such as GSK, Novartis, Pfizer and Sanofi. Now hiring over 9,300 professionals, the sector has become a local pharmaceutical ecosystem and draws international attention and engagement which is encapsulated in global events like Pharmapack Asia.

Singapore also participates in an extensive network of free trade agreements, with regional frameworks such as the ASEAN Free Trade Area creating advantageous conditions for pharmaceutical trade and investment throughout the Asia-Pacific region. These agreements reduce tariff barriers, facilitate customs procedures and establish frameworks for regulatory cooperation that collectively reduce costs and complexity of cross-border pharmaceutical commerce. For pharmaceutical companies exploring regional market entry or supply chain optimization, Singapore's trade agreements provide strategic advantages enabling efficient distribution to regional markets whilst maintaining Singapore operations as regional hubs for manufacturing, distribution or business development activities.

Representing economic integration among a combined population of over 650 million people, and a GDP approaching USD 4 trillion, the ASEAN Economic Community creates substantial pharmaceutical market opportunities accessible from Singapore. Initiatives for pharmaceutical harmonisation like the Common Technical Dossier help improve regulatory efficiency, with Singapore playing key leadership roles in these efforts. Pharmaceutical companies establishing regional operations in Singapore will also see benefits from the city-state's influence in regional regulatory development and its role as a testing ground for regulatory innovations subsequently adopted across ASEAN markets.

Singapore's status as a financial hub makes it especially advantageous for business development, as the city-state is home to the regional headquarters of major banks, investment firms and financial services providers, all of whom are involved in facilitating pharmaceutical transactions, partnerships and investments. This means that commercial discussions can be conducted efficiently alongside the more technical considerations of developing business relationships as part of the region’s pharma sector.

Cultural and practical considerations for pharma companies in Singapore

As Singapore’s primary business language, the prevalence of English creates an accessible environment for international pharma professionals looking to expand into the region. This also explains the popularity of industry events across the country, with Pharmapack Asia taking place at the impressive 120,000 sqm Marina Bay Sands Expo & Convention Centre, bringing together thousands of attendees from across the globe under one roof. The concentration of pharmaceutical industry activity in central Singapore, as well as its relatively compact size, gives attendees the power to schedule customer meetings, facility visits or regulatory consultations alongside their attendance at the show, maximising ROI on your business travel.

With a specific focus on pharmaceutical packaging, this inaugural Asian edition of the established European pharma show addresses a segment of the market where the APAC is demonstrating significant innovation and manufacturing capabilities. With the region’s considerable concentration of packaging suppliers, equipment manufacturers and pharmaceutical companies, the decision to gather them at a single venue not only allows for effective engagement, but also helps participants connect with stakeholders from across the APAC region.

Conference programming at Pharmapack Asia is split into three tracks, addressing the most pressing challenges and issues facing the industry in this critical moment. With discussions around sustainability initiatives, regulatory compliance requirements, patient-centric design and anti-counterfeiting technologies, speakers at the show will represent pharmaceutical companies, packaging suppliers, regulatory authorities and industry experts, all providing their own diverse perspectives on packaging innovation and best practices. The combination of specialised content, focused programming and the host region’s thriving business environment creates concentrated opportunities to deliver packaging excellence for the entire global pharma landscape.